Screener
Relmada Therapeutics, Inc. RLMD Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055059
| Line item | Three months ended / March 31, 2026 | Three months ended / March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchase of short-term investments | (149,517,480) | (487,916) |
| Sale of short-term investments | 14,290,483 | 15,847,629 |
| Net cash (used in)/provided by investing activities | (135,226,997) | 15,359,713 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | 159,999,996 | - |
| Payment of fees for issuance of common stock | (3,360,000) | - |
| ATM Fees | (65,651) | - |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Relmada Therapeutics, Inc.'s investing cash flow?
- Relmada Therapeutics, Inc. (RLMD) reported investing cash flow of -$135.23M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Relmada Therapeutics, Inc.'s investing cash flow decreased by 980.4% year-over-year, from $15.36M to -$135.23M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s investing cash flow?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s investing cash flow has grown at a -2.9% compound annual growth rate (CAGR), from -$54.12M to -$48.14M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Relmada Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude